Suche
Mein Konto
Rescue for Charlie from Bamberg? Hope through gene therapy for Sanfilippo!
Charlie from Bamberg suffers from MPS IIIA, a rare disease. A new gene therapy could bring hope. Support required.
Rescue for Charlie from Bamberg? Hope through gene therapy for Sanfilippo!
Little Charlie from Bamberg is the focus of a moving story that touches the heart of every Cologne citizen. The boy has received the bitter diagnosis of MPS IIIA (Sanfilippo Syndrome), a rare and fatal neurodegenerative disease that, sadly, usually does not even reach adulthood. It is a lysosomal storage disease that primarily attacks the central nervous system and leads to a rapid loss of learned skills. In the past, parents from all over the world formed support groups for those affected by this mysterious disease, but there is currently no approved treatment for Charlie. infranken.de reports about it.
Although Charlie's parents are healthy, they each carry a defective gene, which contributed to their son's illness. An enzyme deficiency causes damage to its cells. Charlie is currently threatened not only with the loss of his previous abilities, but also with a threatening future. His mother, Astrid Reuther, is desperately fighting for a solution while relying on donations as a single mother. She has launched a campaign on gofundme.com to cover the immense financial burden of an estimated two to four million euros for the stay in the USA and the UX111 gene therapy. This innovative therapy could allow Charlie to gain valuable time to laugh, learn and live.
The UX111 gene therapy
In the USA, the company Ultragenyx is developing the gene therapy UX111, which is in the Transpher A study. This therapy could be approved in 2026 and could change the lives of many patients with MPS IIIA. UX111 is administered as a single intravenous infusion and aims to correct the deficiency of the sulfamidase enzyme, which is responsible for the harmful accumulation of heparan sulfate in cells. Estimated information indicates that between 3,000 and 5,000 patients are affected in commercially accessible regions, with a median life expectancy of only 15 years. Ultragenyx has published news about this.
Sufferers of the disease show significant cognitive decline, behavioral problems and, unfortunately, often an early risk of death. However, studies have shown significant gains in cognitive development in treated patients. In the US, the therapy is already one of the approaches classified as “Regenerative Medicine Advanced Therapy” in terms of commitment and hope for Charlie and many others.
The medical background
Gene therapy has attracted a lot of attention in recent years and could revolutionize the treatment of rare genetic diseases. Different strategies are used that aim to correct the genetic material directly. How on Pfizer Pro described, there is the possibility of gene addition, gene editing and gene modulation, which could bring hope for effective therapies for those suffering from similar diagnoses in the future.
The challenge for Charlie and his mother will be to mobilize the support they need to approve and implement this life-changing therapy. It is hoped that Charlie's story can help raise awareness of MPS IIIA and find more solutions for affected families in the future.